Source comparison
Tesamorelin Dosage vs Other GHRH Analogs
Tesamorelin 2mg daily FDA-approved (2010) Phase III, 806 participants From $59.99 Sermorelin 200-300mcg daily Previously approved (withdrawn) Phase III (historical) $44.99-$79.99 CJC-1295 No DAC 100-200mcg 2-3x daily Not approved Phase I/II $35.99 CJC/Ipa Blen
This comparison does not assign a generated winner or score.
- Tesamorelin
- 2mg daily
- FDA-approved (2010)
- Phase III, 806 participants
- From $59.99
- Sermorelin
- 200-300mcg daily
- Previously approved (withdrawn)
- Phase III (historical)
- $44.99-$79.99
- CJC-1295 No DAC
- 100-200mcg 2-3x daily
- Not approved
- Phase I/II
- $35.99
- CJC/Ipa Blend
- 100/100mcg 2-3x daily
- Components studied separately
- $65.99
- The tesamorelin dosage advantage over other GHRH analogs: FDA approval provides the most comprehensive safety and efficacy characterization available for any GHRH peptide. The Phase III validation with 806 participants gives researchers the highest-confidence dosing data in the GHRH class. The stacking guide covers GHRH + GHRP combinations. The half-life chart covers GH peptide timing.